Search results
Showing 3101 to 3150 of 4090 results for patient
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for HTG129Show all sections
Sections for HTG129
In development Reference number: GID-TA11812 Expected publication date: 13 January 2027
In development Reference number: GID-TA11130 Expected publication date: TBC
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
Awaiting development Reference number: GID-TA11019 Expected publication date: TBC
In development Reference number: GID-TA11650 Expected publication date: 18 November 2026
In development Reference number: GID-TA11693 Expected publication date: TBC
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
In development Reference number: GID-TA11592 Expected publication date: TBC
In development Reference number: GID-TA11625 Expected publication date: 16 December 2026
In development Reference number: GID-TA11863 Expected publication date: TBC
Awaiting development Reference number: GID-TA11862 Expected publication date: TBC
In development Reference number: GID-TA11869 Expected publication date: 24 March 2027
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]
In development Reference number: GID-TA11525 Expected publication date: 10 February 2027
Awaiting development Reference number: GID-TA11584 Expected publication date: 08 December 2027
In development Reference number: GID-TA11803 Expected publication date: TBC
In development Reference number: GID-TA11422 Expected publication date: 18 November 2026
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
impact on patients' lives We look back on the guidance we've produced in 2025. Podcasts 17 December 2025 Getting medicines to NHS...
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other...
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
Palliative photodynamic therapy for advanced oesophageal cancer (HTG132)
Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.
View recommendations for HTG132Show all sections
Sections for HTG132
Awaiting development Reference number: GID-TA11497 Expected publication date: TBC
Awaiting development Reference number: GID-TA11308 Expected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
Awaiting development Reference number: GID-TA11199 Expected publication date: TBC
In development Reference number: GID-TA11766 Expected publication date: TBC
In development Reference number: GID-TA11866 Expected publication date: TBC
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)
Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.
The MIST Therapy system for the promotion of wound healing (HTG267)
Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
people before they reach crisis point, diagnosing faster and making sure patients have the right treatment from the start - referral...
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.
Is the use of chlorhexidine body wash associated with increased antimicrobial resistance?
surgical and infection control teams, and should also take into account patient risk factors, such as whether the person is an S. aureus...
Vibegron for treating symptoms of overactive bladder syndrome (TA999)
Evidence-based recommendations on vibegron (Obgemsa) for treating symptoms of overactive bladder syndrome in adults.
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
In development Reference number: GID-TA11352 Expected publication date: TBC